Hypoxia and Hypercoagulability in COVID-19: Chicken or the Egg?
- PMID: 35522846
- PMCID: PMC9590669
- DOI: 10.1097/ALN.0000000000004241
Hypoxia and Hypercoagulability in COVID-19: Chicken or the Egg?
Conflict of interest statement
Competing Interests
Dr. Fernandez-Bustamante has received funding for research not related with the topic of this article from the United States Department of Defense (Washington, D.C.) and the Merck Sharp & Dohme Corp. (Kenilworth, New Jersey) investigator-initiated studies program. The authors are not supported by, nor maintain any financial interest in, any commercial activity that may be associated with the topic of this article.
Comment on
-
Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study.Anesthesiology. 2022 Jul 1;137(1):67-78. doi: 10.1097/ALN.0000000000004239. Anesthesiology. 2022. PMID: 35412597 Free PMC article.
References
-
- Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia: A review. Crit Care Med 2006; 34:871–7 - PubMed
-
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395:1054–62 - PMC - PubMed
-
- Corey KM, Olson LB, Naqvi IA, Morrison SA, Davis C, Nimjee SM, Que LG, Bachelder RE, Kraft BD, Chen L, Nair SK, Levy JH, Sullenger BA: Suppression of fibrinolysis and hypercoagulability, severity of hypoxemia, and mortality in COVID-19 patients: A retrospective cohort study. Anesthesiology 2022; 137:67–78 - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical